Medicine
Nexlizet 180 mg/10 mg tablet
Nexlizet 180 mg/10 mg tablet is a prescription medicine containing Bempedoic acid and Ezetimibe for oral use, marketed by Esperion Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 68°F to 77°F (20°C to 25°C), excursions permitted to 59°F to 86°F…
Key facts
- Active ingredient (INN)
- Bempedoic acid and Ezetimibe
- Brand
- Nexlizet
- Strength
- 180 mg/10 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- Esperion Therapeutics
- Manufacturer
- Esperion Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store at 68°F to 77°F (20°C to 25°C), excursions permitted to 59°F to 86°F (15°C to 30°C). Store and dispense in the original package protected from extreme heat and humidity.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C10B Cholesterol and lipid-lowering medicines, subgroup C10B
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 March 2020
- Identifiers
- RxCUI 2283230, 2283236DailyMed set ID 3fa2108c-0300-47b8-9d34-f762af7c93c6NDC 72426-818Application NDA211617
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle, plastic | 72426-818-03 | Esperion Therapeutics | 9 March 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Bempedoic acid and Ezetimibe is a fixed-dose combination of an adenosine triphosphate-citrate lyase inhibitor and a dietary cholesterol absorption inhibitor. It is available as tablets for oral use. MedsAcross supplies Bempedoic acid and Ezetimibe for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Bempedoic acid and EzetimibeFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Nexlizet prescribing information (Esperion Therapeutics) · U.S. National Library of Medicine, DailyMed
- Nustendi: European public assessment report (EPAR) · European Medicines Agency
Need Nexlizet 180 mg/10 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.